Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus CLARITIN HIVES RELIEF REDITAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus CLARITIN HIVES RELIEF REDITAB.
CLARINEX D 24 HOUR vs CLARITIN HIVES RELIEF REDITAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
10 mg orally once daily
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine